USPTO serial 79019528
Serial No. 79019528
Reviewed by CopyMark Law Group
Reg. 3335355Status 404
- Filing date
- Status date
- Registration date
- Nov 13, 2007
- Examiner
- VERHOSEK, WILLIAM T
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with Serial No. 79019528?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
MARK I PEROFF
Mark I. Peroff Hiscock & Barclay, LLPSeven Times SquareNew York, NY 10036UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical food preservatives, chemical plasticizers for use as high polymer stabilizers for plastics and paints, synthetic chemical polymer stabilizers for use as light stabilizers for plastics and coatings, chemical additives for use in the manufacture of foods, chemical antioxidants for use in the manufacture of drinks, cakes, flavoring agents, dairy products and fish paste products, chemical germination controllers, namely, gibberellins for grapes, oranges and for domestic and agricultural use, diagnostic reagents for in vitro scientific use, diagnostic preparations for in vitro biological tests, namely for urine and blood tests, for blood glucose tests, for cloning tests, all for scientific use, enzyme preparations for in vitro scientific use, soil conditioners, namely soil improving agents and plant growth regulators for agricultural use, and tetrodotoxins for scientific research use; adhesives not for stationery or household purposes; plant growth regulating preparations; fertilizers; ceramic glazings; higher fatty acid for use as food additive; nonferrous metals, namely, actinium, americium, antimony, ytterbium, yttrium, uranium, erbium, gadolinium, gallium, californium, curium, samarium, dysprosium, silicon, mercury, scandium, strontium, cesium, cerium, selenium, bismuth, thallium, thulium, technetium, terbium, tellurium, thorium, neodymium, neptunium, berkelium, barium, fermium, praseodymium, francium, plutonium, protactinium, promethium, holmium, europium, radium, lanthanum, lithium, rubidium and rhenium; non-metallic minerals, namely, sulfur, foundry sand, kaolin, talc, rock salt, diatomaceous earth, acid clay, heavy spar barites, saltpeter, natural graphite, dolomite, cryolite, bentonite, bauxite, fluorite florspa, magnesite, alunite and rock phosphate. photographic supplies, namely, blueprint paper, photographic paper, photographic sensitizers, photographic dry plates, photographic developers, flash powder, photographic fixers and unexposed photographic films; chemical test paper; artificial sweeteners; flour and starch for industrial purposes for manufacturing paper and textiles; unprocessed plastics in primary form; paper pulp for manufacturing purposes and wood pulp for manufacturing purposes | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical preparations, namely, treatment of central nervous system disorders, treatment of peripheral nervous system disorders, treatment of sensory organs disorders, antiallergic medicines, treatment of cardiovascular disorders, treatment of respiratory organs disorders, treatment of digestive organs disorders, hormones for medical purposes, treatment of uro-genital and anal organs disorders, treatment of epidermis disorders, vitamin preparations, amino acid preparations, nutrients, tonics and alternatives, namely nutritional supplements for medical purposes, hemotropic medicines, treatment of metabolism disorders, cellular function activating agents, tumor suppressing agents, treatment of physically caused lesions, treatment of chemically caused disorders, antibiotic preparations, chemotherapeutics, biological preparations for medical purposes, preparations for destroying parasites, agents for dispensing purposes, namely capsules, solvents or gels used as a carrier for pharmaceuticals, diagnostic preparations for medical purposes, radio-isotope markers for therapeutic or diagnostic use, synthetic narcotics, central nervous system depressants, diagnostic preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating medicines, diuretics, hypotensors, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives used for antidiarrheals, laxatives, purgatives, and for gastritis, antacids, hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis, corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, Crohn' s disease, and chronic active hepatitis, estrogen and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents, cataplasms for the treatment of bruises, lumbago and stiff shoulder, pharmaceutical preparations used to treat hair disorders. food enriching supplements and meal replacement powders for treating vitamin deficiencies, anti-coagulants, enzyme preparations for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcomapreparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, encephalitis vaccines, in vitro tetrodotoxins for medical use as anti-spasmodics; antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmosis, naturally occurring drugs for treating pepticulcers, charred drugs for treating peptic ulcers, moxa for treating peptic ulcers; antiseptics, drugs for arteriosclerosis, oncostatic drugs for the treatment of cancer, multienzyme digestants for in vivo use for treatment of indigestion, antifungal antibiotics for treating trichomoniasis and dermatophytosis, antiparkinsonism drugs, minor tranquilizers and anti-anxiety drugs; veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidium in chickens and dysentery in pigs; sanitary preparations for medical use; cedar wood for use as a clothing protector; sanitary preparations for domestic and agricultural use, namely, herbicides, fungicides, insecticides, bactericides and rodenticides and hormone-based preparations for application to domestic and agricultural plants; oiled paper for medical purposes, sanitary masks; wafer for wrapping a dose of powered medicines; gauze for dressings; unit dose capsules sold empty for pharmaceuticals; eye patches for medical use; ear bandages, menstruation bandages, menstruation tampons, sanitary napkins, sanitary panties, absorbent cotton for medical use; adhesive plasters for medical use; bandages for dressings, collodion for medical use. breast-nursing pads, dental impression material, dental cements, dental abrasives, dental mastics; bracelets for medical purposes; incontinence diapers; fly catching paper, mothproofing paper; lactose milk sugar for babies, lactose milk sugar for dispensing use; powdered milk for babies; semen for artificial insemination; dietetic foods adapted for medical purposes, dietetic beverages adapted for medical purposes, baby foods, diabetic bread that is gluten free to accommodate special medical needs and health conditions, edible plant fibers, namely, dietary fibers as additives for food products; ground flaxseed fibers used in dietary supplements | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 11, 2016 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Mar 11, 2016 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Sep 10, 2015 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 17, 2015 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Jun 26, 2015 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Jun 26, 2015 | INPC | INVALIDATION PROCESSED | — |
| Feb 20, 2015 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jun 20, 2014 | C71T | CANCELLED SECTION 71 | — |
| Jan 30, 2014 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 4, 2009 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 27, 2008 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 13, 2008 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 13, 2008 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 13, 2008 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 13, 2007 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 28, 2007 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 8, 2007 | NPUB | NOTICE OF PUBLICATION | — |
| Jul 24, 2007 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Jul 23, 2007 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 23, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 23, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 23, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 23, 2007 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jul 20, 2007 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jul 16, 2007 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Jul 5, 2007 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 5, 2007 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 5, 2007 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jul 3, 2007 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Jul 2, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 2, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 2, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 21, 2007 | CPRA | PRIORITY ACTION MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jun 21, 2007 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jun 13, 2007 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jun 11, 2007 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Apr 27, 2007 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 27, 2007 | ALIE | ASSIGNED TO LIE | — |
| Apr 5, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 5, 2007 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Apr 5, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 5, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 11, 2006 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 10, 2006 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 28, 2006 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Sep 14, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 14, 2006 | PAPER RECEIVED | — | |
| Apr 6, 2006 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 15, 2006 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 15, 2006 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 11, 2006 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 10, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 7, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 6, 2006 | LIMS | LIMITATION OF GOODS/SERVICES FROM IB ENTERED | — |
| Feb 3, 2006 | NWAP | NEW APPLICATION ENTERED | — |
| Feb 2, 2006 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |